title: When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients?
abstract: Icodextrin-based peritoneal dialysis (PD) has many advantages over glucose-based PD. The present study aimed to investigate when icodextrin should be started for better management of cardiovascular status (as defined by echocardiography findings) and residual renal function (RRF). We retrospectively analyzed 40 patients treated with continuous ambulatory PD or automated PD. The patients were divided into these groups: Group A: started icodextrin within 2 weeks after PD onset. Group B: started icodextrin 1 year after PD onset. Group C: started icodextrin 2 years after PD onset. Group D: never used icodextrin during the study period. At the start of PD, we observed no significant difference in left ventricular mass index (LVMI) or urine volume (UV) between the groups. At 4 years, LVMI and UV were both significantly improved in group A compared with group D. The amelioration in LVMI was negatively associated with phosphate elimination. Our study showed that icodextrin preserved RRF and ameliorated left ventricular hypertrophy. Moreover, the timing of icodextrin introduction in PD patients influenced the clinical effects, including progression of cardiac hypertrophy and RRF.
authors.affiliation: Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan. t-hiramatsu@konan.jaaikosei.or.jp
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Hiramatsu
authors.affiliation: Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Hayasaki
authors.affiliation: Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan.
authors.forename: Akinori
authors.initials: A
authors.lastname: Hobo
authors.affiliation: Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Furuta
authors.affiliation: Baxter Limited, Tokyo, Japan.
authors.forename: Koki
authors.initials: K
authors.lastname: Kabu
authors.affiliation: Baxter Limited, Tokyo, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Tonozuka
authors.affiliation: Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan.
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Iida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D005936:Glucans / Q000008:administration & dosage*; D005947:Glucose / Q000008:administration & dosage*; D015312:Hemodialysis Solutions / Q000008:administration & dosage*; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods*; D014462:Ultrafiltration
chemical_list: D005936:Glucans; D015312:Hemodialysis Solutions; D000077607:Icodextrin; D005947:Glucose